X
Hong Kong biotechs IPOs face lower valuations after Ascletis flop
https://pharmaphorum.com/news/hong-kong-biotech-ipos-face-lower-valuations-after-ascletis-flop/
pharma in China
Local partnerships key to pharma’s success in China
China has become more accepting of Western medicines and sees the value of a strong patenting process, opening the door for more foreign trade and mutual benefits.